Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 FEB 9 ... global drug pricing tactics that keep its AIDS drugs—including its key lifesaving drug Kaletra—out of reach for people living with HIV/AIDS around the world.
The video ...
2009 APR 6 ... about the high price charged by Abbott Laboratories Inc. for its key AIDS drug, Kaletra in Mexico, the company has cut its price by twenty percent — from $4688.00 pesos MXN per ...
2009 JUL 6 ... "Ten patients receiving stavudine, lamivudine and lopinavir/ritonavir (Kaletra (R)) for over 6 years were switched from stavudine to tenofovir for 48 weeks. ...
2009 SEP 7 ... have considered two cases of HIV treatment using a combination of lopinavir/ritonavir (Kaletra@) for once daily and twice daily regimens. We have quantified the impact on therapeutic ...
2009 MAR 23 ... doses when administered daily or every other day for 21 days with lopinavir-ritonavir ( Kaletra) in human immunodeficiency virus (HIV)-infected subjects. Three different dosing ...
2009 OCT 5 ... Inhibitor-Sparing Strategy: Results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). Clinical Infectious Diseases, 2009;49(6):892-900). For ...
2009 MAY 25 ... announced that it will cut the price of Abbott Laboratories' lifesaving AIDS drug, Kaletra to $1,067 USD for the public sector hospitals and clinics and $1,591 USD for the private ...
2008 SEP 29 ... Abbott Laboratories, Inc. for the steep price it charges for its key AIDS drug Kaletra in Mexico. The ad, headlined 'Shame on Abbott,' first appeared in the September 6th ...
2008 OCT 20 ... a new tablet formulation of its leading protease inhibitor lopinavir/ritonavir (known as Kaletra(R)), which is the first and only co-formulated protease inhibitor tablet that does not ...
2008 AUG 18 ... using the Meltrex(R) technology, which was also used in the development of Abbott's Kaletra(R) tablets, which combine ritonavir and lopinavir. However, ritonavir on its own ...
2008 AUG 18 ... containing once-daily or twice-daily dosing of Abbott's (NYSE:ABT) protease inhibitor Kaletra(R) (lopinavir/ritonavir) tablet provided similar results for controlling the virus ...
2008 AUG 18 ... containing once-daily or twice-daily dosing of Abbott's (NYSE:ABT) protease inhibitor Kaletra(R) (lopinavir/ritonavir) tablet provided similar results for controlling the virus ...
2008 NOV 10 ... campaign to prompt Abbott Laboratories, Inc. to lower the price for its key AIDS drug Kaletra in Mexico. A direct mail piece arrives this week in Chicago-area mailboxes, specifically ...
2008 SEP 29 ... patients is associated with favourable efficacy and tolerability and in the KLEAN study (kaletra versus lexiva with epivir and abacavir in antiretroviral-naive patients) it was found to ...
2008 AUG 18 ... and efficacy of EPZICOM and Truvada both combined with a boosted protease inhibitor (Kaletra) administered once-daily in adults who had no previous exposure to HIV medicines. The ...
2008 OCT 20 ... needed for the intracranial haemorrhage, but Tipranavir was discontinued and replaced by Kaletra and Saquinavir. Intracranial haemorrhage could be related to Tipranavir and cryptococcal ...
2008 SEP 15 ... patients is associated with favourable efficacy and tolerability and in the KLEAN study (kaletra versus lexiva with epivir and abacavir in antiretroviral-naive patients) it was found to ...
2008 JUL 7 ... HIV suppression. Four years of results of patients randomized to monotherapy in the Only Kaletra (OK) pilot clinical trial are presented."
"Twenty-one HIV-infected ...
2008 AUG 25 ... study was to develop and validate a dissolution test for lopinavir soft gel capsules (Kaletra), using a simulated absorption profile based on in vivo data. Different conditions such ...
